

 Order Name:
 CA27.29

 Test Number:
 2024375

 Revision Date:
 12/12/2022

TEST NAME			METHODOLOGY	LOINC CODE	
CA 27.29			Immunochemiluminometric (ICMA)	17842-6	
SPECIMEN REQU	IREMENTS				
Specimen	Specimen Volume (min)	Specimen Type	Specimen Container	Transport Environment	
Preferred	1mL (0.3)	Serum	Clot Activator SST	Refrigerated	
Instructions	Notes: 0.3 mL (Note: This volume Does NOT allow for repeat testing.)				
	Specimen Type: Red-top tube or gel-barrier tube				
	Specimen Storage: Refrigerated				
	Specimen Collection: If a red-top tube is used, transfer the separated serum to a plastic transport tube.				
	Special Instructions: It is recommended that one assay method be used consistently to monitor a patient's course of therapy. This procedure does				
	not provide serial monitoring; it is intended for one-time use only.				
			days, Frozen: Greater than 1 month		

GENERAL INFORMATION			
Expected TAT	1-2 days		
Clinical Use	The CA 27.29 assay is intended for use in monitoring: 1) disease progression and/or response to therapy in patients with metastatic disease, and 2) disease recurrence in patients treated previously for stages II or III breast carcinoma who are clinically free of the disease. Serial testing in patients who are clinically free of disease should be used in conjunction with other clinical methods for early detection of cancer recurrence. Limitations: Patients with confirmed breast carcinoma frequently have CA 27.29 assay values in the same range as healthy individuals. Elevations may also be observed in patients with non-malignant disease. Results of this test must always be interpreted in the context of morphologic and other relevant data and should not be used alone for a diagnosis of malignancy		
Notes	Labcorp Test Code: 140293		
CPT Code(s)	86300		
Service Provided By	Oklahoma, Inc.		